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Excessive glomerular collagen IV and reactive oxygen species
(ROS) production are key factors in the development of
diabetic nephropathy. Integrin a1b1, the major collagen IV
receptor, dowregulates collagen IV and ROS production,
suggesting this integrin might determine the severity of
diabetic nephropathy. To test this possibility, wild-type and
integrin a1-null mice were rendered diabetic with
streptozotocin (STZ) (100 mg/kg single intraperitoneal
injection), after which glomerular filtration rate (GFR),
glomerular collagen deposition, and glomerular basement
membrane (GBM) thickening were evaluated. In addition,
ROS and collagen IV production by mesangial cells as well as
their proliferation was measured in vitro. Diabetic a1-null
mice developed worse renal disease than diabetic wild-type
mice. A significant increase in GFR was evident in the a1-null
mice at 6 weeks after the STZ injection; it started to decrease
by week 24 and reached levels of non-diabetic mice by week
36. In contrast, GFR only increased in wild-type mice at week
12 and its elevation persisted throughout the study. Diabetic
mutant mice also showed increased glomerular deposition of
collagen IV and GBM thickening compared to diabetic
wild-type mice. Primary a1-null mesangial cells exposed to
high glucose produced more ROS than wild-type cells, which
led to decreased proliferation and increased collagen IV
synthesis, thus mimicking the in vivo finding. In conclusion,
this study suggests that lack of integrin a1b1 exacerbates the
glomerular injury in a mouse model of diabetes by
modulating GFR, ROS production, cell proliferation, and
collagen deposition.
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Diabetic nephropathy, the most common cause of end-stage
renal disease in the developed world, is initially characterized
by glomerular hyperfiltration, glomerular and tubular
epithelial hypertrophy, and microalbuminuria. In established
diabetic nephropathy, glomerular basement membrane
(GBM) thickening, interstitial fibrosis, and glomerular
sclerosis are usually seen (reviewed by Schrijvers et al.1
and van Dijk and Berl2). The sclerosed glomeruli have
excessive extracellular matrix (ECM) accumulation, especially
collagen IV.
A principal mechanism whereby hyperglycemia induces
diabetic nephropathy is by stimulating excessive production
of reactive oxygen species (ROS) from different cell types,
including mesangial cells.3–5 ROS activates pro-fibrotic
molecules, which enhance glomerular ECM deposition.6,7
Hyperglycemia also increases the production of advanced
glycation end-stage products (AGEs) of ECM components in
the mesangium and GBM, resulting in changes in per-
meability of the filtration barrier (reviewed by Forbes et al.8). In
addition, weakening of podocyte- and mesangial cell–matrix
interactions may occur under diabetic conditions owing to
modification of specific arginine residues by reactive carbonyl
compounds within integrin-binding sites of matrix proteins.9
Thus, both the direct effects of glucose, and accumulation of
AGEs and consequent alterations in ECM components of the
kidney influence the pathogenesis of diabetic nephropathy.
Integrin a1b1, the major receptor for collagen IV,10 is
expressed in the endothelial, mesangial, and visceral epithelial
cells of the glomerulus.11,12 Integrin a1b1 is critical to
support cell survival and proliferation on collagen substra-
ta,13 for sensing extracellular collagen levels and down-
regulating its endogenous synthesis.14 Integrin a1-null
mesangial cells produce considerably more ROS than wild-
type cells, which contribute to the pathogenesis of increased
glomerulosclerosis in integrin a1-null mice.15 Moreover,
binding of integrin a1b1 to collagen IV is severely impaired
when this ECM substrate is exposed to reactive carbonyl
compounds that are produced under diabetic conditions.9
Altogether, integrin a1b1 appears to play a key role in
diminishing the induction of ROS-dependent glomerular
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injury and downregulates collagen production found in
sclerosed glomeruli. In these studies, we investigated the role
of this collagen-binding receptor in regulating ROS produc-
tion and collagen IV deposition in the highly prevalent
pathological condition of diabetic kidney disease and provide
evidence that lack of this receptor exacerbates the glomerular
injury in a mouse model of diabetes.
RESULTS
Renal function is impaired in integrin a1-null diabetic mice
Diabetes was induced in Balb/c mice with streptozotocin
(STZ) as described.16,17 Both wild-type and integrin a1-null
mice developed and maintained similar levels of hyperglyce-
mia throughout the 36-week period (Figure 1a) and
exhibited significant weight loss at week 36, although it was
evident by week 24 in the a1-null mice (Figure 1b). Diabetic
integrin a1-null mice also had worse albuminuria at all time
points (Figure 1c). Similar levels of glycemia, body weight,
and albuminuria were observed between non-diabetic wild-
type and integrin a1-null age-matched mice at all time points
(Figure 1a–c).
As there is no published data on renal function in Balb/c
mice under both basal and diabetic conditions, inulin
clearance was evaluated as described.18 Non-diabetic wild-
type and a1-null Balb/c mice had an inulin clearance of
approximately 0.25 ml/min at both the beginning and end of
the study period (Figure 1d). Inulin clearance in diabetic a1-
null mice increased to 0.34 ml/min by week 6 and 0.42 ml/
min by week 12. In contrast to other mouse models of
diabetes, where hyperfiltration continues for at least 25
weeks,19 the inulin clearance of the a1-null mice decreased to
0.32 ml/min by week 24 and reached baseline (0.26 ml/min)
at 36 weeks (Figure 1d). However, in diabetic wild-type mice,
inulin clearance only increased at week 12 and it persisted at
an increased level (0.40 ml/min) to the end of the study
(Figure 1d).
Diabetic a1-null mice develop increased collagen IV
deposition resulting in mesangial expansion and GBM
thickening
Diabetic renal disease in mice is characterized by GBM
thickening and mesangial expansion (reviewed by Schrijvers
et al.1). Light and electron microscopy was performed to
assess differences in these two parameters between the two
genotypes. Both wild-type and integrin a1-null mice
demonstrated increased mesangial expansion (Figure 2a);
however, the increase was more profound in the integrin a1-
null mice at all time points analyzed, as evaluated by the
matrix mesangial expansion index (Figure 2b). Electron
microscopy on kidneys of 36-week non-diabetic wild-type
and a1-null mice showed that the thickness of GBM in the
two genotypes measured approximately 0.1670.03 mm
(Figure 2c). In 36-week diabetic mice, there were similar
degrees of foot process effacement (B50%) in both
genotypes; however, mesangial expansion and GBM thicken-
ing were significantly greater in the diabetic a1-null mice
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Figure 1 | Renal functions in wild type and integrin a1-null mice. (a) Blood glucose levels, (b) body weight, (c) urine albumin/creatinine ratio,
and (d) inulin clearance were measured in vehicle- or STZ-treated mice at the time points indicated. Values represent mean7s.d. of 10 mice per
time point. Differences between untreated and STZ-treated wild-type or a1-null mice (d), or STZ-treated wild-type and STZ-treated a1-null mice
at the same time point (*) were significant with Po0.05.
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(0.56 mm70.06 in the null mice vs 0.32 mm70.07 in the
wild-type mice, Po0.001) (Figure 2c). Thus, lack of integrin
a1 results in increased mesangial expansion and GBM
thickening in diabetic mice.
Collagen IV, the most abundant ECM component in the
glomerulus, is formed by six alpha chains (a1a6) that
assemble into three triple-helical protomers (reviewed by
Hudson et al.20). The a1a1a2 network is found in the
mesangium, GBM, and Bowman’s capsule; the a3a4a5
network in the GBM and the a5a6a5 network in the
Bowman’s capsule (reviewed by Hudson et al.20). As diabetic
integrin a1-null mice have significantly increased mesangial
expansion (Figure 2a and b) and a thickened GBM (Figure
2c), we determined whether this was owing to excessive
collagen IV deposition. Utilizing an anti-a1a2a1 network
antibody, we detected increased mesangial collagen IV
deposition in both wild-type and integrin a1-null diabetic
mice starting at week 6 (Figure 3a); however, significantly
more deposition was evident in the a1-null mice (Figure 3a).
The nature of the a1a2a1 network was verified utilizing a
specific anti-a2(IV) NC1 domain antibody (Figure 3b),
whereas antibodies against the a3–a6 (IV) NC1 domains were
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Figure 2 | Increased mesangial expansion and GBM thickening in diabetic a1-null mice. (a) Kidneys from vehicle- (6 weeks) or STZ-treated
(6–36 weeks) mice were evaluated at time points indicated. Periodic acid Schiff stain, original magnification,  400. (b) The degree of matrix
mesangial expansion was scored in 100 glomeruli per mouse from 10 vehicle- (6 and 36 weeks shown) and STZ-treated (6–36 weeks) mice and
expressed as described in Materials and Methods. (c) Electron microscopy performed on kidneys of 36-week non-diabetic and diabetic mice
revealed significant mesangial expansion (arrow) and GBM thickening (arrowhead) in the diabetic a1-null mice. The thickness of the GBM
(mean7s.d., calculated as described in Materials and Methods) for both non-diabetic and diabetic mice is indicated in the upper corner.
462 Kidney International (2006) 70, 460–470
o r i g i n a l a r t i c l e R Zent et al.: Integrin a1b1 and diabetic nephropathy
W
ild
 ty
pe
Wild type
1
-N
ul
l
1-Null Wild type 1-Null
6w 6w 12w 24w 36w
36-w non-diabetic 36-w diabetic
2
(IV
)
3
(IV
)
4
(IV
)
5
(IV
)
6
(IV
)
Non-diabetica
b
c
Diabetic
0
70
60
50
40
30
20
10
2 3 4 5 6
WT 36-w
1KO 36-w
WT 36-w diabetic
Collagen IV chains
%
 A
re
a 
oc
cu
pi
ed
 b
y 
co
lla
ge
n
IV
-p
os
itiv
e 
st
ru
ct
ur
es
/g
lo
m
er
ul
us
*
*
*
*
*

*
*

*

*

1KO 36-w diabetic
Figure 3 | Increased glomerular collagen IV deposition in a1-null diabetic mice. Kidney sections of vehicle- (6 or 36 weeks shown) and
STZ-treated (6–36 weeks) mice were stained with (a) a polyclonal anti-collagen IV antibody or (b) monoclonal anti-a(IV) chain antibodies as
described in Materials and Methods. Original magnification,  400. (c) The levels of specific collagen IV chains per glomerulus were quantified
using Scion image analysis as described in Materials and Methods. Differences between non-diabetic and diabetic mice (*) or diabetic wild-type
and diabetic a1-null mice (d) were significant with Po0.05.
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used to evaluate collagen deposition in the GBM and/or
Bowman’s capsule. Increased levels of the a3–a6 chains were
present in the kidneys of 36-week diabetic mice when
compared to non-diabetic mice (Figure 3b and c); however,
the increase was more profound in the integrin a1-null mice.
Thus, the integrin a1-null diabetic mice develop more severe
mesangial expansion and GBM thickening owing to increased
deposition of a1a1a2, a3a4a5, and a5a5a6 collagen IV
networks.
Diabetic integrin a1-null mice develop more glomerular AGEs
and decreased cell proliferation
Diabetic nephropathy is characterized by the accumulation of
AGEs in tissues, especially in proteins with a low turnover
rate such as collagens (reviewed by Paul and Bailey21).
Diabetic a1-null mice show increased glomerular collagen IV
production (Figure 3); however, the glycation state and the
functional consequences of glycation have not been char-
acterized. For this reason, glomerular AGE accumulation was
assessed on kidney sections from 36-week non-diabetic and
diabetic mice utilizing an antibody that recognizes carboxy
methyl lysine (CML).22,23 Increased CML staining was
evident in diabetic wild-type and integrin a1-null mice;
however, the area of CML-immunoreactive staining in the
a1-null mice was significantly increased (Figure 4a and b).
The CML staining pattern matched that of the a1a2a1
collagen IV network, suggesting that the majority of the
glycation occurred in this network (Figure 4a).
Increased matrix synthesis and decreased mesangial cell
proliferation is observed in progressive diabetes.1,2 As less
cellularity was observed in the glomeruli of diabetic integrin
a1-null (Figure 2a), glomerular proliferation was assessed in
kidney sections utilizing an antiproliferating cell nuclear
antigen (PCNA) antibody. A similar number of PCNA-
positive cells were detected in the glomeruli of non-diabetic
wild-type and integrin a1-null mice. As expected, glomerular
cell proliferation decreased in both diabetic genotypes at 36
weeks; however, this decrease was significantly more in a1-
null mice relative to age-matched non-diabetic mice. A
3377% reduction in PCNA-positive cells per glomerulus was
observed in diabetic wild-type mice vs a 5276% reduction in
diabetic a1-null mice compared to their non-diabetic
controls. Thus, increased mesangial AGE production in
integrin a1-null mice correlated with decreased cell pro-
liferation, suggesting that excessive collagen IV glycation may
alter the proliferative potential of mesangial cells.
AGE-modified collagen IV decreases mesangial cell
proliferation and migration
Glycation of ECM proteins has been reported to inhibit
cell–matrix interactions resulting in alterations in osteoblast
adhesion24 and mesangial proliferation;25 however, the
mechanism is poorly understood. As integrin a1b1 is
the major receptor for collagen IV and the binding site
for this receptor in collagen IV is modified by reactive
carbonyl compounds produced under diabetic conditions,9
we investigated whether this integrin played any specific role
in mediating the pathological effects of glycated collagen IV
on mesangial cell behavior.
AGE-modified collagen IV was prepared by incubating
mouse collagen IV (a1a2a1 network) with increasing
concentrations of D-glucose. The degree of AGE modifica-
tion, verified by enzyme-linked immunosorbent assay
(ELISA) utilizing an anti-CML antibody, directly correlated
with glucose concentrations (Figure 5a). Similar to our
previous results,15 adhesion of a1-null mesangial cells to
collagen IV was significantly less than that of wild-type
mesangial cells (Figure 5b). There was no further inhibition
of cell adhesion upon modification of collagen IV by glucose
(Figure 5b) consistent with our recent observation that
modification of lysine residues in collagen IV does not affect
mesangial cell adhesion.9 In contrast to the adhesion results,
glycated collagen IV greatly reduced both wild-type and
integrin a1-null mesangial cell growth (Figure 5c), and this
reduction paralleled the degree of glycation. However, the
inhibition of growth on glycated collagen IV was propor-
tional in both cell types, suggesting that this effect was not
dependent on integrin a1b1 expression.
The effect of glycated collagen IV on cell migration was
determined using transwells coated with collagen IV with or
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Figure 4 | Increased glomerular age accumulation in a1-null
diabetic mice. (a) Kidney sections of vehicle- (36 weeks) and
STZ-treated (36 weeks) mice were stained with anti-collagen IV
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without different concentrations of glucose. The degree of
glycation correlated with the glucose concentrations (Figure
6a). Integrin a1-null mesangial cells migrated significantly
less than wild type on non-glycated collagen IV (Figure 6b),
and on glycated collagen IV both cell types migrated
proportionately less than cells placed on unmodified collagen
IV (Figure 6b). Similar to the proliferation assay, alterations
in cell migration on glycated collagen appear to be integrin
a1b1-independent.
Effect of high glucose on mesangial cell functions
Oxidative stress and ROS are key factors in the development
of diabetic nephropathy (reviewed by Forbes et al.8).
Although podocytes and renal tubular cells produce ROS,
the major source of ROS in the kidney is the nicotinamide
adenine dinucleotide phosphate (reduced form) oxidase
complex found in the mesangial cells.26 Integrin a1-null
mesangial cells produce excessive ROS at baseline, which,
together with a direct effect of lack of integrin a1, results in
decreased mesangial cell proliferation and increased collagen
IV production.15 To determine the effect of high glucose on
ROS production, mesangial cells were grown in low (5 mM)
and high (30 mM) glucose, following which ROS levels were
measured. Cells of both genotypes produce more ROS when
grown in 30 mM compared to 5 mM glucose; however,
ROS production by a1-null cells was significantly greater
(Figure 7a).
The contribution of increased ROS production on
mesangial cell growth was determined in the presence of
low or high glucose. Glucose (30 mM) enhanced wild-type
mesangial cell growth, as reported previously,27,28 whereas it
significantly inhibited growth of integrin a1-null cells (Figure
7b). These results suggested that elevated ROS production in
the a1-null mesangial cells might be the cause for their
decreased proliferation. When mesangial cells were grown in
30 mM glucose with the antioxidants 4-hydroxy-2,2,6,
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Figure 5 | Effect of glycated collagen IV on cell adhesion and
proliferation. (a) The 96-well plates were coated with 20mg/ml
mouse collagen type IV and incubated with 0, 5, 30, and 100 mM
glucose. After 45 days, an ELISA was performed to detect CML-
modified collagen IV. Values are the mean7s.d. of three wells.
(b) Mesangial cells (5 104) were plated for 1 h in serum-free onto
96-well plates coated as described in (a) and adhesion measured as
described in Materials and Methods. Data represent the mean7s.d.
of three experiments. (c) Mesangial cells (5 103) were plated
onto 96-well plates coated as described in (a) and proliferation
evaluated as described in Materials and Methods. Values are changes
relative to wild-type cells grown on non-glycated collagen, and
are averages of three experiments. Differences between wild-type or
a1-null cells plated on untreated vs glucose-treated wells (d), or
wild-type and a1-null cells within the same treatment group (*)
were significant with Po0.05.
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Figure 7 | Effect of high glucose on ROS production. (a) Mesangial
cells were incubated on 20 mg/ml collagen IV with glucose at
concentrations indicated and ROS generation was evaluated 72 h
later as described in Materials and Methods. Data are the mean7s.d.
of three experiments. (b) Mesangial cells were incubated as described
above and proliferation evaluated 72 h later as described in Materials
and Methods. Values are changes relative to wild-type cells cultured
in 5 mM glucose, and are averages of three experiments. Differences
between wild-type and a1-null cells within the same treatment group
(*), or a1-null or wild-type cells treated with 30 vs 5 mM glucose (d),
were significant with Po0.05. (c) Mesangial cells were incubated with
30 mM glucose with or without antioxidants (AOX) and proliferation
evaluated 72 h later. Values are changes relative to wild-type cells
cultured without antioxidants, and are averages of three experiments.
Differences between wild-type and a1-null cells within the same
treatment group (*), or a1-null cells untreated vs AOX-treated (d),
were significant with Po0.05.
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6-tetramethylpiperidine-1-oxyl and diphenyleneiodonium, a
significant increase in proliferation was only seen in a1-null
mesangial cells (Figure 7c). These results confirm that
increased ROS production by the a1-null mesangial cells is
responsible for decreased cell proliferation at diabetic glucose
levels.
As high glucose29 and increased ROS production15 result
in increased collagen IV production by mesangial cells,
collagen IV expression was evaluated in wild-type and
integrin a1-null mesangial cells grown in low and high
glucose. Integrin a1-null mesangial cells grown in 5 mM
glucose produced significantly more collagen IV mRNA
(Figures 8a and b) and protein (Figures 8c and d) than wild-
type cells. At 30 mM glucose, both wild-type and integrin a1-
null cells produced more collagen IV mRNA and protein;
however, this increase was much more pronounced in the a1-
null cells. To determine whether the increased collagen IV
deposition by a1-null mesangial cells was exclusively induced
by ROS production, collagen IV production was evaluated in
the presence of antioxidants. The amount of collagen IV in
the integrin a1-null cells grown in high glucose with
antioxidants was reduced, but not to the level of wild-type
cells (Figures 8c and d). These results suggest that both
increased ROS and lack of integrin a1b1 per se contribute to
the increased collagen synthesis in hyperglycemic conditions.
In addition, our data confirm the observation that treatment
with antioxidants reduces ECM deposition by mesangial cells
grown in high glucose.29
DISCUSSION
The multiple effects of hyperglycemia on renal hemo-
dynamics as well as metabolic and growth factor-dependent
pathways result in the development of diabetic nephropathy.
Although diabetic mice do not acquire all the characteristics
of human diabetic nephropathy, they develop hyperfiltration,
albuminuria, mesangial matrix expansion, and GBM thick-
ening (reviewed by Breyer et al.30). We utilized integrin a1-
null mice to explore the role of this collagen IV receptor and
key regulator of ROS production15 on the severity of diabetic
nephropathy. We demonstrate that integrin a1-null mice
develop worse diabetic nephropathy than wild-type controls.
In contrast to wild-type mice, the a1-null mice develop
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Values represent the mean7s.d. of 10 images per treatment. Differences between wild-type (WT) and a1KO (knockout) cells within the same
treatment group (d), mesangial cells grown in low vs high glucose (*) or mesangial cells grown in high glucose with or without AOX (**) were
significant with Po0.05.
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hyperfiltration soon after the induction of diabetes and they
show a subsequent decrease in hyperfiltration to levels similar
to those seen in age-matched control mice 36 weeks after STZ
injection. The glomerular lesions, characterized by increased
mesangial collagen IV deposition, GBM thickening, and
glomerular AGEs are worse in the mutant mice. In vitro,
AGE-modified collagen IV decreases proliferation and
migration of mesangial cells of both genotypes equally,
suggesting that glycation influences cell functions in an
integrin a1b1-independent manner. In contrast, high glucose
induces significant increases in ROS production in integrin
a1-null mesangial cells, with consequent inhibition of cell
proliferation and increased collagen IV expression/deposi-
tion. Thus, integrin a1b1 plays a key role in regulating the
degree of glomerulosclerosis in a mouse model of diabetes.
Increased glomerular filtration rate (GFR), a characteristic
of early onset of diabetic nephropathy, plays a critical role in
the pathogenesis of glomerulosclerosis. Usually, the GFR
decreases in late stages of nephropathy in humans and
precedes end-stage renal failure. In most mouse strains
(C57BL/6J, DBA/2J, FVB/NJ, MRL/MpJ, and KK/HlJ), there
is only an increase in GFR, which is still present 25 weeks
after the onset of diabetes.19 Changes in GFR varies greatly
between mouse strains rendered diabetic; however, there are
no published mouse models in which hyperfiltration
diminishes.19,30 We demonstrate that wild type Balb/c mice
display similar patterns to other mouse strains. However,
when these mice are placed on the integrin a1-null mice
background, they not only develop hyperfiltration sooner
than wild-type mice following STZ injection but also show
decreased GFR to levels seen in non-diabetic mice by week
36. Thus, the initial increase of GFR followed by a decrease in
the integrin a1-null mice simulates the pathophysiological
changes of human diabetic nephropathy better than most
published mouse models of this condition.
The severity of mesangial expansion and GBM thickening
of the diabetic integrin a1-null mice is in keeping with our
previous observation that they develop more glomerulo-
sclerosis than wild-type mice following adriamycin injec-
tion.15 In this model, excessive production of glomerular
collagen IV was related to both lack of integrin a1-mediated
downregulation of collagen IV synthesis and increased ROS
production. As diabetic nephropathy is characterized by
increased ROS production, it is likely that similar mecha-
nisms account for the increased mesangial expansion in both
the diabetic (this paper) and adriamycin models.15
Kidneys from diabetic wild-type and a1-null mice
demonstrated increased expression of the a1a1a2, a3a4a5,
and a5a5a6 collagen IV networks. These data agree with the
observations that mRNA for these chains is increased in
kidneys of diabetic KKAy mice,31 and that mesangial and
endothelial cells upregulate the synthesis of some chains
when grown in high glucose.32 Increased expression
of collagen IV networks was more prominent in the integrin
a1-null mice both in euglycemic and diabetic states, sugges-
ting that integrin a1b1 controls the synthesis of all the
chains of collagen IV in both physiological and pathological
conditions.
Integrin a1-null mice have greatly increased levels of AGEs
and the staining pattern was similar to the a1a2a1 (IV)
network. This result suggests that the predominant glycated
protein in the diabetic glomerulus is collagen IV, in
agreement with studies showing that the amount of glycated
glomerular collagen correlates with progression of nephro-
pathy.33 In humans, AGE accumulation in the mesangium,
GBM, and tubular basement membranes is evident in diffuse
and nodular diabetic nephropathy,33 and glomerular accumu-
lation of AGEs has also been found in rats with experimental
diabetes.34,35
Glycation of collagen IV did not alter the ability of wild-
type or a1-null mesangial cells to adhere to collagen;
however, it resulted in decreased cell migration and
proliferation in both genotypes. The adhesion results for
a1-null mesangial cells on non-glycated collagen IV are
similar to those published previously.15 However, the effects
of the glycation of collagen IV on cell adhesion contrast with
the finding that glycated collagen I inhibits osteoblast
adhesion,24 but agree with our recent finding that carbonyl
products of glucose metabolism, rather than glucose itself,
inhibit adhesion of mesangial cells to collagen IV by
interfering with integrin a1b1-mediated cell adhesion.9 The
result that glycated collagen IV inhibits mesangial cell
proliferation is similar to that found by others,25 and the
observation that integrin a1b1 seems to play little or no role
in inhibition of cell growth and migration on AGE-modified
collagen IV suggests that these alterations in cell functions are
integrin a1b1-independent events.
In contrast, the effects of glucose itself and oxidative stress
were quite different on wild-type and a1-null mesangial cells.
The antiproliferative effect of high glucose on integrin a1-
null mesangial cells correlates with increased ROS production
and is reversed by incubation with antioxidants. The
decreased proliferation of a1-null cells in high glucose is
likely owing to toxic levels of ROS, similar to cells exposed to
adriamycin.15 Increased ROS production by a1-null mesan-
gial cells also upregulate collagen synthesis; however, this
upregulation was also modulated by an integrin a1-
dependent/ROS-independent mechanism,14,15 as treatment
with antioxidants only partially reduced collagen IV deposi-
tion in the a1-null cells. The observation that collagen IV
deposition was ameliorated following antioxidant treatment
agrees with the finding that treatment with antioxidants
reduces ECM deposition by mesangial cells grown in high
glucose.29
This paper describes the first example of a genetic model,
where lack of an integrin results in an altered host response to
diabetes-induced renal injury. There are, however, a number
of studies showing alterations in expression and distribution
of integrins in diabetic kidneys.36 Of note, increased staining
for a1, a2, and a3 integrin subunits was observed in the
mesangium of human kidneys with moderate diabetic
nephropathy and further increased in severe diabetic
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nephropathy,37 suggesting that integrin a1b1 expression
correlates directly with the degree of diabetic nephropathy.
In view of our data, it is conceivable that increased
glomerular expression of integrin a1b1 in diabetic kidneys
might be the result of a ‘defense’ mechanism of injured
mesangial cells trying to upregulate a receptor that in
physiological conditions downregulates both collagen14 and
ROS15 generation.
In conclusion, diabetic a1-null mice, lacking the major
collagen IV receptor, develop worse mesangial expansion and
greater GBM thickening than control mice. The increased
fibrotic response is mediated by both ROS-dependent and -
independent mechanisms; however, AGE-modified collagen
IV does not appear to play a significant mechanistic role.
Thus, integrin a1b1 is a potent modifier of diabetic-induced
glomerular disease in mice and this integrin could potentially
be viewed as a genetic determinant of sclerosis in human
diabetic nephropathy.
MATERIALS AND METHODS
Mice and experimental procedure
All experiments were performed according to institutional animal
care guidelines. Wild-type and integrin a1-null male mice on a pure
Balb/c background (5 weeks old, B20 g) received a single
intraperitoneal injection of streptozotocin (Sigma, St Louis, MO,
USA) (100 mg/kg dissolved in citrate buffer (pH 4.5)) as
described16,17 and were subsequently killed 0, 6, 12, 24, and 36
weeks post-STZ injection. Control mice were injected with citrate
buffer only and killed at the same time points indicated above. Ten
mice per genotype were used for each time point and two
independent experiments were performed.
Clinical parameters and morphologic analysis
Body weight was measured weekly and expressed in grams. Blood
glucose levels were monitored weekly using the Lifescan One Touch
Glucose Meter (Lifescan Inc., Milpitas, CA, USA) and expressed as
mg/dl. Urine (24-h collection) was collected at the time of killing
and albumin and creatinine were measured by ELISA as described15
and expressed as mg albumin/mg creatinine. Fluorescein isothiocya-
nate–inulin clearance, expressed as ml/min/mouse, was measured in
conscious mice as described.18
Paraffin kidney sections were stained with periodic acid Schiff
stain to evaluate glomerular injury. The mesangial matrix expansion
index was evaluated as described previously.15 Briefly, 100 random
glomeruli per mouse were evaluated blindly by a renal pathologist.
Glomeruli were classified depending on the percentage of tuft with
visibly expanded mesangial matrix within each glomerulus and
divided into the following four groups: normal (0% mesangial
expansion), mild (1–29% mesangial expansion), medium (30–59%
mesangial expansion), and severe (60–100% mesangial expansion).
Ten mice for each treatment group were evaluated with a total of
1000 glomeruli examined in each group. The mesangial matrix
expansion index was expressed as mean7s.d.
Electron microscopy
Renal cortices of 36-week non-diabetic and diabetic wild-type and
integrin a1-null mice (three mice per genotype) were fixed in 2.5%
glutaraldehyde, post-fixed in OsO4, dehydrated in ethanol, and
embedded in resin. Glomeruli were then selected from toluidine
blue-stained thick sections and cut for thin sections. Ultrastructural
assessment of glomerular pathologic changes was performed using a
Morgagni transmission electron microscope (FEI, Eindhoven, The
Netherlands). GBM thickening was assessed by point to point
measurements using a 2 2K camera (Advanced Microscopy
Techniques Corp., Danvers, MA, USA) with the associated digital
imaging software. Ten different segments of GBM per mouse from
three mice were measured with a total of 30 measurements in each
treatment group. Values are mean7s.d. The 36-week experimental
group was chosen for analysis as maximum differences in matrix
deposition and basement membrane thickness were observed
between diabetic wild-type and integrin a1-null mice at this time
point (see Figures 2 and 3).
Immunohistochemistry and immunofluorescence
Collagen IV chains were detected by indirect immunofluorescence
on frozen kidney sections, using monoclonal antibodies specific for
NC1 domains. Mouse monoclonal antibody 8D1 against a3(IV)
NCI was produced in the Molecular Recognition Shared Facility of
Vanderbilt University. Rat monoclonal antibodies H22 against
a2NC1, RH42 against a4NC1, b14 against a5NC1, and b66 against
a6NC1 were used as described.38–42 Secondary antibodies used were
fluorescein isothiocyanate-conjugated anti-mouse or anti-rat IgG
(1:300; Jackson Laboratories, West Grove, PA, USA).
a1a2a1 collagen IV network staining, using rabbit anti-mouse
collagen IV antibodies (1:100; Biodesign, Saco, ME, USA) and PCNA
staining using rabbit anti-mouse PCNA antibodies (1:100; Santa
Cruz, Santa Cruz, CA, USA), were performed on paraffin kidney
sections as described.15 The glomerular proliferation index was
expressed as (number of PCNA-positive glomerular cells/total
number of glomerular cells) 100. Ten glomeruli per kidney
were evaluated with a total of 10 kidneys per genotype per time
point.
The formation of CML was determined on frozen kidney sections
stained with the rabbit anti-AGE antibody R618 (1:200),22,23 followed
by incubation with fluorescein isothiocyanate-conjugated anti-
rabbit IgG (1:200; Jackson). Glomerular staining was compared to
that obtained with the anti-a1a2a1 network described above.
Quantification of glomerular collagen IV or AGE-modified collagen
was performed using Scion Image Program, as described.43 Collagen
or modified collagen was expressed as percentage of area occupied
by collagen IV or CML-positive structures per glomerulus. Ten
glomeruli per mouse with a total of 10 mice per time point were
analyzed.
For cellular staining, primary mesangial cells (isolated and
cultured as described15) were cultured on uncoated chamber slides
for 72 h (in order to allow matrix deposition) with 0.1% fetal calf
serum and 5 mM glucoseþ 25 mM mannitol or 30 mM glucose, or
30 mM glucose with the antioxidants 4-hydroxy-2,2,6,6-tetramethyl-
piperidine-1-oxyl (5mM) and diphenyleneiodonium (0.5mM), as
described previously.15 The doses of 4-hydroxy-2,2,6,6-tetramethyl-
piperidine-1-oxyl, a superoxide mimetic, and diphenyleneiodonium,
a specific nicotinamide adenine dinucleotide phosphate oxidase
inhibitor, were chosen because they represent the maximum dose
able to inhibit ROS generation in wild-type and a1-null cells without
cytotoxic effects (data not shown). Immunofluorescence was carried
out using the rabbit anti-a1a2a1 network antibody described above
(1:100) and 2mg/ml 40,6-diamidine-20-phenylindole dihydrochloride
to visualize nuclei. Quantification of glomerular collagen IV was
performed using Scion Image Program, as described.43
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Preparation of glucose-modified collagen IV
Ninety-six-well plates or transwells containing filters with 8-mm
pores (Corning, Acton, MA, USA) were coated with 20 mg/ml mouse
collagen IV (Sigma) in phosphate-buffered saline overnight at 41C.
Immobilized collagen was then incubated with 200 mM sodium
phosphate buffer, pH 7.5, with 0, 5, 30, and 100 mM D-glucose at
371C for 45 days. CML formation was measured by ELISA using the
anti-AGE antibody described above.23
RNA analysis
Mesangial cells were cultured for 72 h with Dulbecco’s modified
Eagles’s medium containing 0.1% fetal calf serum and 5 mM
glucoseþ 25 mM mannitol or 30 mM glucose. RNA was isolated
using a single-step isolation kit (TRIzol, Invitrogen, Carlsbad, CA,
USA) and 10 mg were separated in formaldehyde-containing 1%
agarose gels, transferred to nylon membranes (Nytran Supercharge,
Schleicher & Schuell, Keene, NH, USA), and hybridized with 32P-
labeled cDNAs for mouse a1(IV) collagen. Mouse b2-tubulin was
used for normalization. Collagen IV and tubulin bands were
quantified by densitometry analysis using an Alpha Imager 2000
(Alpha Innotech, San Leandro, CA, USA) and collagen IV signal
expressed as collagen IV/tubulin. Three independent experiments
were performed.
Adhesion assays
Microtiter plates (96-well) coated with unglycated or glycated
mouse collagen IV prepared as described above were used for
standard mesangial cell adhesion assays performed as described
previously.15 Three independent experiments were performed in
quadruplicate.
Proliferation assay
Primary mesangial cells (5 103 ) were plated on to 96-well plates
coated with 20 mg/ml mouse collagen IV in Dulbecco’s modified
Eagles’s medium containing 2% fetal calf serum with 5 mM
glucoseþ 25 mM mannitol or 30 mM glucose, or with 30 mM glucose
together with the antioxidants 4-hydroxy-2,2,6,6-tetramethylpi-
peridine-1-oxyl (5 mM) and diphenyleneiodonium (0.5 mM).15 Low
serum (2%) was used as at this dose wild-type and integrin
a1-null cells equally adhere to collagen and the direct effect of
collagen IV on cell proliferation can be easily evaluated.13 In some
experiments, mesangial cells were plated on glycated mouse collagen
IV prepared as described above. Two days after plating, the medium
was replaced, the cells were pulsed for an additional 48 h with
3H-thymidine (1mCi/well), and processed as described.43
Migration assay
Cell migration was assayed in transwells containing filters with 8 mm
pores (CorningWare) coated with 20 mg/ml of unglycated or
glycated mouse collagen IV prepared as described above. Mesangial
cell migration was then performed as described.44 Three indepen-
dent experiments were performed in duplicate.
Detection of ROS
Mesangial cells were cultured in six-well plates in Dulbecco’s
modified Eagles’s medium containing 0.1% fetal calf serum with
5 mM glucoseþ 25 mM mannitol or 30 mM glucose. After 3 days,
ROS were detected using dihydro-rhodamine (Sigma) as described
previously.15 Three independent experiments were performed in
duplicate.
Statistical analysis
The Student’s t-test was used for comparisons between two groups
and analysis of variance using Sigma-Stat software for statistical
differences between multiple groups. Po0.05 was considered
statistically significant.
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